SHZ:002082

Wanbangde Pharmaceutical Holding Group Co., Ltd. · SHZ · Healthcare · CNY · FY for 2025

Figures on this page computed 2026-11-08 12:50 UTC

Last close

n/aCNY

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
CNY
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.32Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.8%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
CNY
- computed

Growth is the furthest below its sector's middle: 0.04 against 0.50 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.18x

-1.85x

-2.28x

0.97x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales0.18x
Its own average over 10 years, 6.28B.
Profit-1.85x
Its own average over 10 years, 107.5M.
Free cash flow-2.28x
Its own average over 10 years, -138.1M.
Debt0.97x
Its own average over 10 years, 835.5M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at -2.28 times.

Sales is 0.18 times its own 10-year average; Profit is -1.85 times its own 10-year average; Free cash flow is -2.28 times its own 10-year average; Debt is 0.97 times its own 10-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 10-year average0.18
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit against its own 10-year average-1.85
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Free cash flow against its own 10-year average-2.28
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Debt against its own 10-year average0.97
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
CNY